El interés en corto de Oryzon Genomics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Oryzon Genomics. Los datos de interés en corto se actualizan cada dos semanas.

Oryzon Genomics (OTC:ORYZF) Bolsa, Informe de interés en corto

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics SA

<ul>
<li>Following this successful lease amendment, the completed closing of the 11 community International JV / Welltower Portfolio, and the expected closings of the remaining previously-announced acquisition of 30 communities from two additional currently leased portfolios, the Company has largely cleared its lease maturities through 2029. After giving effect to these transactions, Brookdale will own over 75% of its consolidated units, marking another significant step in the Company's efforts to increase its owned real estate portfolio, benefiting from the economics of ownership, while substantially improving the cash flow profile and reducing risk associated with its overall leased portfolio.</li>
<li>The Company expects the Ventas lease amendment to provide a $15+ million improvement to the Company's 2025 cash flows.(1) Beginning in 2026, the Company expects additional cash flow improvement, including continued operating income growth, the benefit of continued appropriate expense management relative to the Company's portfolio size, partially offset by incremental rent expense.</li>
</ul>

News

Health Care

General

Brookdale Senior Living Has Entered Into Mutually Beneficial Agreements With Ventas To Amend Its Triple-Net Master Lease Arrangement, Which Can Potentially Provide Over $15M Improvement To The Company's 2025 Cash Flows

Biotech

Large Cap

Merck Announced Topline Results From Two Phase 3 Trials Of Doravirine/Islatravir In Adults With HIV-1 Infection That Is Virologically Suppressed On Different Antiretroviral Therapy Regimens, Trials Met Efficacy Success Criteria For Non-inferiority To Comparator Antiretroviral Therapies

Accenture continues to expect GAAP operating margin for fiscal 2025 to be in the range of 15.6% to 15.8%, an expansion of 80 to 100 basis points from fiscal 2024 GAAP operating margin, and an expansion of 10 to 30 basis points from fiscal 2024 adjusted operating margin, which excludes $438 million for business optimization costs. &nbsp;
For fiscal 2025, the company continues to expect operating cash flow to be in the range of $9.4 billion to $10.1 billion; property and equipment additions to be $600 million; and free cash flow to be in the range of $8.8 billion to $9.5 billion. &nbsp;

Guidance

Accenture Raises FY25 Revenue Growth To 4% - 7% In Local Currency, Compared To 3% - 6% Previously; Revises GAAP EPS Outlook From $12.55 - $12.91 To $12.43 - $12.79, Est $12.74

Ahead of rising tensions between Beijing and Washington, a Chinese cybersecurity center has accused the United States of engaging in cyberattacks to steal business secrets.
What Happened: The National Computer Network Emergency Response Technical Team/Coordination Centre of China, a non-governmental organization focused on cybersecurity threats, claims to have detected and mitigated these cyberattacks, South China Morning Post<a href="https://www.scmp.com/news/china/politics/article/3291521/chinese-cybersecurity-centre-accuses-us-hacking-and-stealing-tech-secrets?module=top_story&amp;pgtype=homepage"> reported</a> on Thursday.
Since August, an advanced material design research unit in China has reportedly been targeted by suspected American intelligence agencies. The attackers allegedly exploited a vulnerability in an electronic document security system to access the company&#8217;s server, deploying a Trojan horse virus to over 270 hosts, thereby stealing commercial secrets.
See Also: <a href="https://www.benzinga.com/trading-ideas/24/12/42536470/costco-warns-that-tariffs-raise-prices-trump-team-says-trade-policies-will-make-life-affordable?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Costco Warns That Tariffs Raise Prices, Trump Team Says Trade Policies Will &#8216;Make Life Affordable&#8217;</a>
Another incident in May 2023 involved a breach in Microsoft Exchange software, affecting a major hi-tech enterprise specializing in smart energy and digital information. The center&#8217;s recent weekly report highlighted coordination with various organizations to manage 146 network security incidents, including 92 cross-border cases. 
Additionally, 2,950 data security breaches were identified. Meanwhile, the US has initiated a national security investigation into Chinese router company TP-Link, amid ongoing accusations and denials between the two nations regarding state-sponsored hacking activities.
Why It Matters: The accusations from China come <a href="https://www.benzinga.com/news/global/24/12/42559347/trump-administration-could-ban-amazons-top-selling-routers-linked-to-chinese-cyberattacks-report">amid heightened scrutiny</a> of Chinese technology firms by the United States. The U.S. government is currently investigating TP-Link for potential national security threats, as the company holds a significant share of the US router market. This follows multiple cyberattacks linked to TP-Link&#8217;s routers.
Furthermore, the FBI has issued warnings about ongoing <a href="https://www.benzinga.com/24/12/42333675/fbi-warns-of-ongoing-china-backed-telecom-hacks-heres-how-encrypted-messaging-could-be-your-last-line-of-defense">China-backed telecom hacks</a>, advising Americans to use encrypted messaging apps to protect their communications. Jeff Greene, CISA's executive assistant director for cybersecurity, emphasized the importance of encryption in safeguarding data, even if intercepted. These developments underscore the escalating cybersecurity tensions between the two global powers.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/24/12/42513807/trump-says-softbanks-100b-commitment-to-us-is-monumental-demonstration-of-confidence-in-americas-future?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Says SoftBank&#8217;s $100B Commitment To US Is &#8216;Monumental Demonstration Of Confidence In America&#8217;s Future&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

China Accuses US Of Cyber Espionage And Theft Of Business Secrets Amid Rising Tensions

DA Davidson analyst Alex Platt initiates coverage on IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy rating and announces Price Target of $50.

Price Target

Initiation

Analyst Ratings

IONQ

DA Davidson Initiates Coverage On IonQ with Buy Rating, Announces Price Target of $50

OCU410 (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

OCGN

Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study

This represents 5% to 9% growth in local currency, reflecting the company's assumption of an approximately negative 2.5% foreign-exchange impact compared with the second quarter of fiscal 2024.

Accenture Expects Q2 Revenues Of $16.2B - $16.8B, Est $16.625B

Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) reported quarterly earnings of $3.59 per share which beat the analyst consensus estimate of $3.39 by 5.9 percent. The company reported quarterly sales of $17.69 billion which beat the analyst consensus estimate of $17.12 billion by 3.31 percent. This is a 9.03 percent increase over sales of $16.22 billion the same period last year.

Earnings

Earnings Beats

Accenture Q1 2025 GAAP EPS $3.59 Beats $3.39 Estimate, Sales $17.69B Beat $17.12B Estimate

On Wednesday, the FDA approved Mesoblast Limited&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42566997/mesoblasts-ryoncil-is-the-first-u-s-fda-approved-mesenchymal-stromal-cell-msc-therapy" rel="noreferrer noopener">therapy in the U.S</a>.
Ryoncil is the only MSC therapy approved in the U.S. for any indication and the only therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents.
Ryoncil contains MSCs, a type of cell that can have various roles in the body and can differentiate into multiple other types of cells. These MSCs are <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host" rel="noreferrer noopener">isolated</a> from the bone marrow of healthy adult human donors.&nbsp;
Steroid-refractory acute graft-versus-host disease is a serious condition that can occur as a complication of allogeneic hematopoietic (blood) stem cell transplantation (allo-HSCT).
In allo-HSCT, a patient receives hematopoietic stem cells from a healthy donor to replace their stem cells and form new blood cells.
This procedure is often performed as part of treatment for certain types of blood cancers, blood disorders, or immune system disorders.
Annually, in the U.S., approximately 10,000 patients undergo an allogeneic bone marrow transplant, 1,500 of whom are children.
Approximately 50% develop aGvHD, and almost half of those do not respond to steroids, the recognized first-line treatment.
In a single-arm multi-center Phase 3 trial of children with SR-aGvHD, 89% of whom had high severity Grade C or Grade D disease, 70% achieved an overall response by Day 28 of treatment with Ryoncil, a measure that predicts survival in aGVHD.
Study participants who had a partial or mixed response to treatment—meaning that there was improved condition in one organ with either no change (partial) or worsening condition (mixed) in another organ—received additional infusions once weekly for an additional four weeks.
Sixteen study participants (30%) had a complete response to treatment 28 days after receiving Ryoncil, while 22 participants (41%) had a partial response.
Ryoncil treatment was not discontinued or interrupted in any patient for any laboratory abnormality, and the full course was completed without interruption in more than 85% of patients.
Price Action: MESO stock is up 42.60% at $17.47 during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/downgrades/24/12/42561430/match-group-analyst-flags-tinder-woes-industry-challenges-for-stock-downgrade" target="_blank" rel="noreferrer noopener">Match Group Analyst Flags Tinder Woes, Industry Challenges For Stock Downgrade</a></li>
</ul>

Movers

Trading Ideas

MESO

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Wedbush analyst Nick Setyan reiterates Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Outperform and maintains $200 price target.

Reiteration

TXRH

Wedbush Reiterates Outperform on Texas Roadhouse, Maintains $200 Price Target

Lamb Weston Declared Quarterly Dividend Of $0.37 Per Share, Depicting $0.01 Increase, Dividend Is Payable On February 28

On Wednesday, December 18th, U.S. markets closed sharply lower, with the Dow dropping over 1,100 points—its steepest decline since August and longest losing streak since 1974. The Fed cut rates by 25 basis points as expected but signaled fewer cuts in 2025. Markets reacted sharply to the less dovish tone despite assurances of economic strength and progress on inflation.
Fed Chair Powell adopted a hawkish tone as the Fed cut rates by 0.25% but reduced 2025 rate cut projections to two, down from four in September and below market expectations.
The U.S. current account deficit widened to $310.9 billion in Q3, exceeding the estimated $284 billion. Housing starts fell 1.8% in November to an annualized 1.289 million units from 1.312 million in October.
S&amp;P 500 ended in the red, with consumer discretionary, real estate, and communication services stocks suffering the largest declines.
The Dow Jones Industrial Average was down 2.58% and closed at 42,326.87, the S&amp;P 500 closed lower by 2.95% at 5,872.16, and the Nasdaq Composite slipped 3.56% to finish at 19,392.69.
Asia Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 declined 0.80% and ended the session at 38,808.50, led by losses in the Communication, Steel, and Transportation Equipment sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 1.70% and ended the day at 8,168.20, led by losses in the Gold, IT, and Materials sectors.</li>
<li>India&#8217;s Nifty 50 slid 0.98% to 23,961.95, and Nifty 500 was down 0.77%, closing at 22,757.65, led by losses in the Banking, Consumer Durables, and Capital Goods sectors.</li>
<li>China&#8217;s Shanghai Composite fell 0.36% to close at 3,370.03, while the Shenzhen CSI 300 gained 0.09%, finishing the day at 3,945.46.</li>
<li>Hong Kong&#8217;s Hang Seng was down 0.56% and closed the session at 19,752.51.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 1.60%.</li>
<li>Germany&#8217;s DAX slid 1.12%.</li>
<li>France&#8217;s CAC fell 1.49%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 1.27%.</li>
<li>European stocks fell as the Fed signaled slower rate cuts in 2025. Rate-sensitive tech stocks led losses, while bond yields spiked and commodities declined.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.71% at $70.08/bbl, and Brent was up 0.07% at $73.44/bbl.</li>
<li>Natural Gas rose 2/16% to $3.447.</li>
<li>Gold was trading lower by 0.78% at $2,632.79, Silver was down 2.23% to $30.027, and Copper fell 1.62% to $4.0903.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.40%, S&amp;P 500 futures rose 0.48% and Nasdaq 100 futures gained 0.47%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. dollar index was down 0.13% to 107.89, the USD/JPY rose 1.35% to 156.89, and the USD/AUD slid 0.42% to 1.6012.</li>
<li>The U.S. dollar surged to a two-year high after the Fed signaled fewer rate cuts in 2025, pressuring global currencies. However, it slipped Thursday amid thin holiday trading, with the euro and Canadian dollar, and won fluctuating sharply.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Global Markets Slide On Fed's Hawkish Rate Policy; U.S. Dollar Eases Slightly After Hitting Two-Year High - Global Markets Today While US Slept

Management

Zomedica Appoints Scott Jordan As Its Executive Vice President, Finance And CFO, Effective January 1, 2025

Combined with the Bitcoin held prior to this purchase, Hut 8's strategic Bitcoin reserve now totals 10,096 Bitcoin with a market value of more than $1 billion as of December 18, 2024.&nbsp;
Based on publicly available information, the Company believes this positions it as one of the ten largest corporate owners of Bitcoin in the world.&nbsp;
The 10,096 Bitcoin held in reserve were acquired through low-cost production and the strategic at-market purchase announced today for a realized average cost of $24,484 per Bitcoin.
&nbsp;

Hut 8 Reveals Purchase Of Approximately 990 Bitcoin; Aggregate Purchase Price Of Acquired Bitcoin Was $100M, Or An Average Of $101,710 Per Bitcoin

Canoo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) shares are trading lower in <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">the premarket session on Thursday.</a>
The company is grappling with major financial challenges, leading to the furlough of 82 employees and the temporary shutdown of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42564360/canoo-announces-furloughs-and-factory-idle-as-it-focuses-on-finalizing-securing-capital" rel="noreferrer noopener">its factories in Oklahoma</a>.
The move comes as the electric vehicle manufacturer works to secure the necessary capital to continue its operations.
Canoo is currently in advanced discussions with multiple capital sources but acknowledges the tough decision to furlough staff, particularly during the holiday season. The company expressed hope of bringing employees back once its financial situation stabilizes.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42569953/dow-dips-over-1100-points-falling-for-10th-session-as-powell-adopts-hawkish-stance-greed-index-moves-to-fear-zone" rel="noreferrer noopener">Dow Dips Over 1,100 Points, Falling For 10th Session As Powell Adopts Hawkish Stance: Greed Index Moves To &#8216;Fear&#8217; Zone</a>
Canoo said, &#8220;We regret having to furlough our employees, especially during the holidays, but we have no choice at this point. We are hopeful that we will be able to bring them back to work soon.&#8221;
In its third quarter reported in November, the company revealed a quarterly cash outflow of $31.3 million, down 20.7% from the second quarter and <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41956101/canoo-q3-earnings-revenue-miss-eps-beat-continued-operations-consolidation-and-more" rel="noreferrer noopener">down 58.6% on a year-over-year basis</a>.
As of the end of the third quarter, the company had $16 million in cash, cash equivalents, and restricted cash. Canoo is focused on consolidating operations and reducing costs, which includes a shift in its manufacturing footprint from California to Texas and Oklahoma, the company said in a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41954695/canoo-inc-announces-third-quarter-2024-results" rel="noreferrer noopener">release dated November 14.</a>
This restructuring is expected to save the company $12 million to $14 million annually.
&#8220;This will continue to be a difficult and critical period as we do everything we can to get the capital in place, bring jobs back online, and get back on track with our step-level manufacturing plan,&#8221; said Tony Aquila, Investor, Executive Chairman, and CEO in November.
Price Action: GOEV shares are trading lower by 6.59% to $0.1177 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42569883/quantum-computing-rigetti-d-wave-skyrocket-up-to-300-in-5-sessions-after-google-unveils-willow-chip-but-analysts-urge-caution-not-every-tiktok-guitarist-is-the-next-taylor-swift" target="_blank" rel="noreferrer noopener">Quantum Computing, Rigetti, D-Wave Skyrocket Up To 300% In 5 Sessions After Google Unveils Willow Chip, But Analysts Urge Caution: &#8216;Not Every TikTok Guitarist Is The Next Taylor Swift&#8217;</a></li>
</ul>

Equities

GOEV

Why Is Penny Stock Canoo Falling On Thursday?

Pro forma for repayment, the convertible debt facility with Petrichor will be approximately $19 million and maintain a maturity of September 2027.&nbsp;

FENC

Fennec Pharmaceuticals Announced The Early Repayment Of $13M Of Its Approximately $32M Outstanding Convertible Debt Facility With Petrichor Healthcare Capital Management

Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) new vehicle registrations in the EU are continuing to drop,&nbsp;<a href="https://www.benzinga.com/tech/24/11/41892379/tesla-offers-a-year-of-supercharging-for-free-in-europe-as-it-chases-record-q4-deliveries-to-outpace-a-slowdown" target="_blank" rel="noreferrer noopener">threatening the company's global EV delivery target</a>&nbsp;for the year.
What Happened:&nbsp;Tesla had 18,786 new vehicle registrations in the European Union in November, marking a drop of 41% from the corresponding period last year, according to data from the European Automobile Manufacturers&#8217; Association (ACEA).
Battery electric vehicle registrations overall fell 9.5% in the EU last month to 130,757 units owing to the drop in major markets such as France and Germany.
For the full year 2023, Tesla delivered 1,808,581 vehicles around the globe. To mark a growth over last year, the company has to deliver at least 514,926 vehicles in the three months through the end of December. Tesla has never managed to deliver over 500,000 EVs in a quarter to date, making this an ambitious target.
Why It Matters:&nbsp;According to Tesla researcher&nbsp;Troy Teslike, the low sales in Europe are likely to impact Tesla's aim to prevent a drop in yearly deliveries.
&#8220;While sales have increased in China, they aren&#8217;t enough to fully offset the decline. Tesla is still trying to avoid a drop in total car sales this year compared to last year, but they're struggling with demand problems in the US and Europe,"&nbsp;<a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher" target="_blank" rel="noreferrer noopener">Teslike said</a>&nbsp;in a post on X earlier this month.
As per ACEA data, Tesla had 211,405 new vehicle registrations in the EU from January through the end of November, marking a drop of over 15% year-on-year.
Price Action:&nbsp;Tesla stock fell 8.3% on Wednesday to close at $440.13. Year-to-date, the stock is up 77.2%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways" target="_blank" rel="noreferrer noopener">Jim Cramer Thinks Trump&#8217;s Plans For Robotaxis Are ‘Fanciful,&#8217; But He Is Still Bullish On Tesla Stock: ‘The Musk Premium Will Work Its Magic In Other Ways&#8217;</a></li>
</ul>
Photo courtesy: Tesla

Global

Tech

TSLA

Tesla EU Registrations Plunge 41% In November, Casting Shadow On Q4 Target Of Over 500,000 EV Deliveries

President-elect Donald Trump unexpectedly dismissed a <a href="https://www.benzinga.com/24/12/42544562/congressional-leaders-reach-bipartisan-deal-to-avert-government-shutdown">bipartisan proposal</a> on Wednesday, increasing the possibility of a U.S. government ahead of Christmas.
However, according to research firm Edward Jones, markets tend to look through the noise, with U.S. stocks staying positive half the times during the past 20 government shutdowns since 1976.
What Happened: &#8220;The uncertainty that a potential government shutdown introduces can lead to a short-term uptick in volatility. But as with most political events, government shutdowns have historically had little lasting impact on equity performance,&#8221; said Angelo Kourkafas, an investment strategist at Edward Jones.
Recent years have witnessed recurring government shutdowns, though they have been relatively short-lived. Since 1976, the U.S. has experienced 20 such shutdowns lasting at least a day. The most prolonged shutdown, occurring in December 2018, lasted for 35 days, setting a historical record.
The following table shows how the markets have reacted to the previous shutdowns. According to this data, the stocks were positive half the time during the government closures and were higher in most cases three and six months later.
<h3 class="wp-block-heading">Market Performance Over Last 20 Shutdowns Since 1976</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Start Date</td>
<td>Duration in days</td>
<td>During Shutdown</td>
<td>Three Months Later</td>
<td>Six Months Later</td>
</tr>
<tr>
<td>9/30/1976</td>
<td>11</td>
<td>-3%</td>
<td>2%</td>
<td>-4%</td>
</tr>
<tr>
<td>9/30/1977</td>
<td>13</td>
<td>-3%</td>
<td>-5%</td>
<td>-3%</td>
</tr>
<tr>
<td>10/31/1977</td>
<td>9</td>
<td>1%</td>
<td>-2%</td>
<td>4%</td>
</tr>
<tr>
<td>11/30/1977</td>
<td>9</td>
<td>-1%</td>
<td>-5%</td>
<td>7%</td>
</tr>
<tr>
<td>9/30/1978</td>
<td>18</td>
<td>-2%</td>
<td>-2%</td>
<td>0%</td>
</tr>
<tr>
<td>9/30/1979</td>
<td>12</td>
<td>-4%</td>
<td>5%</td>
<td>-1%</td>
</tr>
<tr>
<td>11/20/1981</td>
<td>3</td>
<td>0%</td>
<td>-8%</td>
<td>-6%</td>
</tr>
<tr>
<td>9/30/1982</td>
<td>2</td>
<td>1%</td>
<td>15%</td>
<td>25%</td>
</tr>
<tr>
<td>12/17/1982</td>
<td>4</td>
<td>1%</td>
<td>11%</td>
<td>25%</td>
</tr>
<tr>
<td>11/10/1983</td>
<td>4</td>
<td>1%</td>
<td>-6%</td>
<td>-5%</td>
</tr>
<tr>
<td>9/30/1984</td>
<td>3</td>
<td>-2%</td>
<td>1%</td>
<td>9%</td>
</tr>
<tr>
<td>10/3/1984</td>
<td>2</td>
<td>0%</td>
<td>0%</td>
<td>10%</td>
</tr>
<tr>
<td>10/16/1986</td>
<td>2</td>
<td>0%</td>
<td>11%</td>
<td>20%</td>
</tr>
<tr>
<td>12/18/1987</td>
<td>2</td>
<td>0%</td>
<td>9%</td>
<td>8%</td>
</tr>
<tr>
<td>10/5/1990</td>
<td>4</td>
<td>-2%</td>
<td>-1%</td>
<td>19%</td>
</tr>
<tr>
<td>11/13/1995</td>
<td>6</td>
<td>1%</td>
<td>8%</td>
<td>11%</td>
</tr>
<tr>
<td>12/15/1995</td>
<td>22</td>
<td>0%</td>
<td>6%</td>
<td>7%</td>
</tr>
<tr>
<td>9/30/2013</td>
<td>17</td>
<td>3%</td>
<td>7%</td>
<td>8%</td>
</tr>
<tr>
<td>1/19/2018</td>
<td>3</td>
<td>1%</td>
<td>-5%</td>
<td>0%</td>
</tr>
<tr>
<td>12/21/2018</td>
<td>35</td>
<td>10%</td>
<td>11%</td>
<td>14%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Edward Jones Research</figcaption></figure>
&#8220;More broadly, market performance tends to be driven more by the outlook for economic growth, earnings and interest rather than the political landscape,&#8221; added Kourkafas.
See Also: <a href="https://www.benzinga.com/24/12/42550804/bofa-says-cash-holdings-of-asset-managers-in-december-2024-has-been-the-lowest-since-2011-and-2002-triggering-a-sell-signal">Cash Holdings Of Asset Managers Lowest In 13 Years, Says BofA, Flagging &#8216;Sell&#8217; Signal Amid &#8216;Trump 2.0 Optimism&#8217;</a>
Why It Matters: The impact of a shutdown could be different on various kinds of government functions. It differs from a debt-limit default in that it doesn&#8217;t hinder the government&#8217;s capacity to meet its debt obligations to bondholders, meaning it doesn&#8217;t directly influence borrowing costs or credit ratings.
While Treasury interest payments and Social Security benefits continue as usual, millions of federal workers go without pay during the shutdown. Although this situation affects households, furloughed employees will receive backpay once Congress restores funding.
What&#8217;s Happening With The Bill? After scrapping the bipartisan proposal, Trump urged House Speaker Mike Johnson and Republican lawmakers to renegotiate, just days before federal funding was set to expire.
Speaker Johnson has to now come up with an alternative plan to prevent the government from closing ahead of Friday's deadline.
In a statement, Trump and Vice President-elect JD Vance urged Republicans to "get smart and tough."
Trump's proposal, which was seen as highly ambitious, called for continued government funding alongside a contentious provision to raise the national debt ceiling—something that typically faces strong opposition from his own party. "Anything else is a betrayal of our country," they declared.
Department of Government Efficiency co-lead Elon Musk, on the other hand, also supported the Republicans in turning down the bill.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The voice of the people was heard. This was a good day for America. <a href="https://t.co/r8K4AcbDYf">https://t.co/r8K4AcbDYf</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1869521075761234338?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42569883/quantum-computing-rigetti-d-wave-skyrocket-up-to-300-in-5-sessions-after-google-unveils-willow-chip-but-analysts-urge-caution-not-every-tiktok-guitarist-is-the-next-taylor-swift">Quantum Computing, Rigetti, D-Wave Skyrocket Up To 300% In 5 Sessions After Google Unveils Willow Chip, But Analysts Urge Caution: &#8216;Not Every TikTok Guitarist Is The Next Taylor Swift&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Politics

Trump's Rejection Of Bipartisan Deal Fuels Government Shutdown Fears: How Markets Historically React To Political Turmoil

With the acquisition of the new shares, Sony will become KADOKAWA's largest shareholder, holding approximately 10% of its shares, including the shares Sony previously acquired in February 2021.
At this time, Sony does not plan to acquire additional KADOKAWA shares after the execution of the acquisition.
This capital and business alliance is not anticipated to have a material impact on Sony's consolidated financial results for the fiscal year ending March 31, 2025.

Sony Group Corporation American Depositary Shares

SONY

Sony Signs Strategic Capital And Business Alliance Agreement For Purpose Of Acquiring 12.05M New KADOKAWA Shares For Approximately 50B Yen - Filing

Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/SGMO/news">pre-market trading</a>.
Astellas and Sangamo Therapeutics disclosed Capsid license agreement to deliver genomic medicines for neurological diseases.
Sangamo Therapeutics shares jumped 19.5% to $2.81 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) gained 219.5% to $6.39 in pre-market trading after jumping 54% on Wednesday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) climbed 170% to $2.13 in pre-market trading after declining over 50% on Wednesday.</li>
<li>AppTech Payments Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) gained 170% to $1.03 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) gained 68% to $3.55 in pre-market trading after dropping 26% on Wednesday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 44.5% to $17.70 in pre-market trading. Mesoblast&#8217;s RYONCIL became the first FDA-approved mesenchymal stromal cell therapy in the U.S.</li>
<li>Elevai Labs Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 38.6% to $2.98 in pre-market trading after gaining 9% on Wednesday.</li>
<li>Dallasnews Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) gained 38% to $6.72 in pre-market trading after falling 5% on Wednesday.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) rose 28% to $2.68 in pre-market trading after jumping 44% on Wednesday.</li>
<li>XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) gained 24.2% to $2.67 in pre-market trading after dipping more than 90% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 40.5% to $0.4847 in pre-market trading after jumping 348% on Wednesday.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) declined 36.4% to $0.42 in pre-market trading after jumping more than 80% on Wednesday.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) shares fell 20.5% to $6.00 in pre-market trading.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares dipped 18.6% to $63.50 in pre-market trading as the company posted downbeat quarterly results and lowered FY25 outlook.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) fell 18.5% to $0.5213 in today's pre-market trading after jumping 52% on Wednesday.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) dipped 15.6% to $87.60 in pre-market trading. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
<li>Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) fell 15.6% to $2.00 in pre-market trading after surging 39% on Wednesday.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares fell 14.5% to $2.95 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) fell 14.3% to $0.3008 in pre-market trading following a 30% plunge on Wednesday.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) fell 14.2% to $5.10 in pre-market trading after declining 5% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Pre-Market Outlook

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

Comments

Oryzon Genomics

Interés en corto

Oryzon Genomics (OTC:ORYZF) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL